Discovering novel pharmacogenomic biomarkers by imputing drug response in cancer patients from large genomics studies.
暂无分享,去创建一个
Fan Wang | Aritro Nath | Robert L Grossman | Paul Geeleher | R. Grossman | R. S. Huang | Paul Geeleher | Fan Wang | Zhenyu Zhang | Robert F. Gruener | A. Nath | G. Morrison | S. Bhutra | Zhenyu Zhang | Robert F Gruener | Gladys Morrison | Steven Bhutra | R Stephanie Huang
[1] Francisco Azuaje,et al. Computational models for predicting drug responses in cancer research , 2016, Briefings Bioinform..
[2] Nancy J. Cox,et al. Consistency in large pharmacogenomic studies , 2016, Nature.
[3] Fupan Yao,et al. Tissue specificity of in vitro drug sensitivity , 2016, bioRxiv.
[4] N. Cox,et al. Cancer biomarker discovery is improved by accounting for variability in general levels of drug sensitivity in pre-clinical models , 2016, Genome Biology.
[5] N. Schultz,et al. OncoKB: Annotation of the oncogenic effect and treatment implications of somatic mutations in cancer. , 2016 .
[6] J. Mesirov,et al. DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets , 2016, Clinical Cancer Research.
[7] Melissa C. Skala,et al. Drug response in organoids generated from frozen primary tumor tissues , 2016, Scientific Reports.
[8] Michael P. Morrissey,et al. Pharmacogenomic agreement between two cancer cell line data sets , 2015, Nature.
[9] M. Maitland,et al. Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics. , 2015, Journal of the National Cancer Institute.
[10] Joshua M. Korn,et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response , 2015, Nature Medicine.
[11] Large-Scale Drug Screens Support Precision Medicine. , 2015, Cancer discovery.
[12] Joshua A. Bittker,et al. Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. , 2015, Cancer discovery.
[13] William E. Evans,et al. Pharmacogenomics in the clinic , 2015, Nature.
[14] R. Finley,et al. A novel ER–microtubule-binding protein, ERLIN2, stabilizes Cyclin B1 and regulates cell cycle progression , 2015, Cell Discovery.
[15] Steffen Falgreen,et al. Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models , 2015, BMC Cancer.
[16] Qing Zhao,et al. Combining multidimensional genomic measurements for predicting cancer prognosis: observations from TCGA , 2015, Briefings Bioinform..
[17] R. Lanfear,et al. The Extent and Consequences of P-Hacking in Science , 2015, PLoS biology.
[18] Patrick Aloy,et al. Drug sensitivity in cancer cell lines is not tissue-specific , 2015, Molecular Cancer.
[19] Nci Dream Community. A community effort to assess and improve drug sensitivity prediction algorithms , 2014 .
[20] Paul Geeleher,et al. pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels , 2014, PloS one.
[21] S. Dudoit,et al. Normalization of RNA-seq data using factor analysis of control genes or samples , 2014, Nature Biotechnology.
[22] Benjamin J. Raphael,et al. Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin , 2014, Cell.
[23] Adam A. Margolin,et al. Assessing the clinical utility of cancer genomic and proteomic data across tumor types , 2014, Nature Biotechnology.
[24] S. Barollo,et al. The combination of RAF265, SB590885, ZSTK474 on thyroid cancer cell lines deeply impact on proliferation and MAPK and PI3K/Akt signaling pathways , 2014, Investigational New Drugs.
[25] Robert L. Grossman,et al. Bionimbus: a cloud for managing, analyzing and sharing large genomics datasets , 2014, J. Am. Medical Informatics Assoc..
[26] D. Amadori,et al. Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer , 2014, Expert opinion on pharmacotherapy.
[27] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[28] Laura M. Heiser,et al. A community effort to assess and improve drug sensitivity prediction algorithms , 2014, Nature Biotechnology.
[29] N. Cox,et al. Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines , 2014, Genome Biology.
[30] Benjamin Haibe-Kains,et al. Inconsistency in large pharmacogenomic studies , 2013, Nature.
[31] H. Hollema,et al. Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL , 2013, British Journal of Cancer.
[32] Gary D Bader,et al. Comprehensive identification of mutational cancer driver genes across 12 tumor types , 2013, Scientific Reports.
[33] S. Gabriel,et al. Pan-cancer patterns of somatic copy-number alteration , 2013, Nature Genetics.
[34] Joshua M. Stuart,et al. The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.
[35] Robert Gentleman,et al. Software for Computing and Annotating Genomic Ranges , 2013, PLoS Comput. Biol..
[36] X. Hua,et al. Interaction of the oncogenic miR-21 microRNA and the p53 tumor suppressor pathway. , 2013, Carcinogenesis.
[37] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[38] P. Hirth,et al. Vemurafenib: the first drug approved for BRAF-mutant cancer , 2012, Nature Reviews Drug Discovery.
[39] N. Moatamed,et al. High concordance between HercepTest immunohistochemistry and ERBB2 fluorescence in situ hybridization before and after implementation of American Society of Clinical Oncology/College of American Pathology 2007 guidelines , 2012, Modern Pathology.
[40] S. Ramaswamy,et al. Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.
[41] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[42] Paul L Appleton,et al. The microtubule poison vinorelbine kills cells independently of mitotic arrest and targets cells lacking the APC tumour suppressor more effectively , 2012, Journal of Cell Science.
[43] G. Clayman,et al. MEK Inhibitor PD0325901 Significantly Reduces the Growth of Papillary Thyroid Carcinoma Cells In vitro and In vivo , 2010, Molecular Cancer Therapeutics.
[44] H. Allgayer,et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer , 2008, Oncogene.
[45] J. Fletcher,et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] K. Coombes,et al. Microarrays: retracing steps , 2007, Nature Medicine.
[47] Xin Huang,et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.
[48] M. Ostland,et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[50] J F Barrett,et al. Identification of CDK4 as a target of c-MYC. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[51] J. Bonneterre,et al. Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[52] D. Pinkel,et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. , 1992, Proceedings of the National Academy of Sciences of the United States of America.